Transarterial chemoembolization (TACE)
Sponsors
Sun Yat-sen University, Shandong Cancer Hospital and Institute, Seoul National University Hospital, Guangdong Provincial People's Hospital, Juan Sanabria, MD
Conditions
AdenocarcinomaBCLC Stage B Hepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaCarcinomaCarcinoma, HepatocellularCirculating Tumor Cell;DOXORUBICIN/TRASTUZUMAB [VA Drug Interaction]Digestive System Neoplasms
Phase 1
Phase 2
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
NCT01556815
Start: 2012-05-31End: 2015-05-31Target: 40Updated: 2012-04-25
Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection
NCT05213637
Start: 2018-04-25End: 2023-04-30Target: 430Updated: 2022-02-07
Neoadjuvant TACiE in Locally Advanced Gastric Cancer
NCT05346874
Start: 2022-06-01End: 2025-05-01Target: 37Updated: 2022-05-26
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
RecruitingNCT07239245
Start: 2025-11-12End: 2030-11-10Target: 30Updated: 2025-11-25
Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
RecruitingNCT07293468
Start: 2024-04-01End: 2034-12-31Target: 106Updated: 2025-12-19
Phase 3
Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma
CompletedNCT00493402
Start: 2007-07-31End: 2010-12-31Updated: 2012-12-17
A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular Carcinoma
WithdrawnNCT02004210
Start: 2013-04-30End: 2018-04-30Updated: 2016-04-27
Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma
NCT02646137
Start: 2015-01-31End: 2023-12-31Target: 50Updated: 2018-01-09
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
Active, not recruitingNCT03778957
Start: 2018-11-30End: 2026-08-31Updated: 2026-01-16
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Active, not recruitingNCT04712643
Start: 2021-03-12End: 2029-02-01Updated: 2026-01-30
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
Active, not recruitingNCT05301842
Start: 2022-03-28End: 2027-02-26Updated: 2025-01-15
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
Not yet recruitingNCT06089382
Start: 2023-11-01End: 2026-11-01Target: 104Updated: 2023-10-18
Phase 4
Unknown Phase
Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence
CompletedNCT02032368
Start: 2010-07-31End: 2012-12-31Updated: 2014-01-10
Chemoembolization With or Without Stereotactic Body Radiosurgery for Liver Cancer
WithdrawnNCT02304445
Start: 2015-11-30End: 2017-11-30Updated: 2015-11-26
Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM
CompletedNCT06038552
Start: 2002-01-01End: 2023-05-01Updated: 2025-02-26
TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma
CompletedNCT07053202
Start: 2021-10-01End: 2023-12-31Updated: 2025-07-08
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Not yet recruitingNCT07281664
Start: 2026-01-01End: 2029-12-31Target: 30Updated: 2025-12-15
Using Machine Learning to Identify Responders to TACE or HAIC for uHCC
CompletedNCT07368530
Start: 2015-01-01End: 2025-12-31Updated: 2026-01-26